


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method of imaging or treating a tumor in a mammal comprising:
administering an effective amount of a compound of the formula (I) to said mammal:



wherein the moiety $\begin{array}{c} \text{X} \\ | \\ [\text{Co}] \\ | \\ \text{C} \end{array}$ is cobalamin, $\begin{array}{c} \text{O} \\ || \\ \text{C} \end{array}$ is the residue of a monocarboxylic acid of cobalamin, X is CN, OH, methyl or adenosyl, Y is a linking group and Det is a detectable chelating group comprising a radionuclide or a paramagnetic metal ion; and optionally detecting the compound of formula I in a tumor of the mammal.

2. (currently amended) The ~~compound~~ method of claim 1 wherein the radionuclide is a metallic radioisotope.

3. (currently amended) The ~~compound~~ method of claim 2 wherein the metallic radioisotope is Tc⁹⁹, In¹¹¹ or Gd¹⁵³.

4. (currently amended) The ~~compound~~ method of claim 1 wherein $\begin{array}{c} \text{O} \\ || \\ \text{C} \end{array}$ is the residue of the (b)-monocarboxylic acid.

5. (currently amended) The ~~compound~~ method of claim 4 wherein Y is a divalent monomer, dimer or trimer of $N(H)(CH_2)_{2-6}N(H)$.

6. (currently amended) The ~~compound~~ method of claim 5 wherein Y is $--N(H)(CH_2)_4NH--$.

7. (currently amended) The ~~compound~~ method of claim 1 wherein Det is EDTA, DTPA, DOTA, TETA, or DCTA.

8. (currently amended) The ~~compound~~ method of claim 3 wherein Det comprises DTPA.

9 - 13 (cancelled).

14. (currently amended) A ~~The method of claim 1, evaluating kidney, liver, spleen or intestinal function in a mammal~~ comprising administering to said mammal a detectable amount of a the compound of ~~claim 1~~ in combination with a pharmaceutically acceptable vehicle, and detecting the presence of said compound in ~~the~~ a tumor of the kidney, liver, pancreas, spleen, or intestine of said mammal.

15. (original) The method of claim 14 wherein the administration is parenteral.

16. (original) The method of claim 15 wherein the administration is intravenous.

17. (original) The method of claim 16 wherein the administration is intraperitoneal.

18. (original) The method of claim 14 wherein the administration is oral.

19. (cancelled)

20. (currently amended) The method of claim ~~19~~ 1 wherein the administration is parenteral.

21. (currently amended) The method of claim ~~19~~ 1 wherein the administration is oral.

22. (currently amended) The method of claim ~~19~~ 14 wherein the vehicle is an aqueous vehicle.

23. (currently amended) The method of claim ~~19~~ 2 wherein the tumor is a liver, kidney, splenic, pancreatic, or gastrointestinal tumor.

24. (new) The method of claim 2 wherein the metallic radioisotope is selected from the group consisting of Antimony-124, Antimony-125, Arsenic-74, Barium-103, Barium-140, Beryllium-7, Bismuth-206, Bismuth-207, Cadmium-109, Cadmium-115m, Calcium-45, Cerium-139, Cerium-141, Cerium-144, Cesium-137, Chromium-51, Cobalt-56, Cobalt-57, Cobalt-58, Cobalt-60, Cobalt-64, Erbium-169, Europium-152, Gadolinium-153, Gold-195, Gold-199, Hafnium-175, Hafnium-175-181, Indium-111, Iridium-192, Iron-55, Iron-59, Krypton-85, Lead-210, Manganese-54, Mercury-197, Mercury-203, Molybdenum-99, Neodymium-147, Neptunium-237, Nickel-63, Niobium-95, Osmium-185+191, Palladium-103, Platinum-195m, Praseodymium-143, Promethium-147, Protactinium-233, Radium-226, Rhenium-186, Rubidium-86, Ruthenium-103, Ruthenium-106, Scandium-44, Scandium-46, Selenium-75, Silver-110m, Silver-111, Sodium-22, Strontium-85, Strontium-89, Strontium-90, Sulfur-35, Tantalum-182, Technetium-99m, Tellurium-125, Tellurium-132, Thallium-204, Thorium-228, Thorium-232, Thallium-170, Tin-113, Titanium-44, Tungsten-185, Vanadium-48, Vanadium-49, Ytterbium-169, Yttrium-88, Yttrium-90, Yttrium-91, Zinc-65, and Zirconium-95.

U.S.S.N. 10/620,273

Amdt. dated Aug. 8, 2005

Reply to Office action of Feb. 9, 2005

25. (New) The method of claim 1 wherein Det comprises a chelating group selected from the group consisting of EDTA, DTPA, DOTA, TETA, DCTA, 15N4, 12N3, 2-p-nitrobenzyl-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, and BAT.